We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TMO:NYSEThermo Fisher Scientific Inc Analysis

Data as of 2026-09-01 - not real-time

$600.50

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

The moving-average structure behind Thermo Fisher Scientific Inc. is bullish at $600.50, with short-term averages leading the long-term ones. Across the trailing 30 sessions it gained 14.7%. RSI sits at 52.3, which reads as neutral, and MACD momentum is bearish. Watch $564.40 as support and $647.00 as the nearer resistance level.
The shares look fair, trading on 32.3 times earnings in line with a sector average of 30.6. The average analyst target implies 5.1% above today's level. Revenue is growing at 10.5% on a 15.0% profit margin. The 0.30% dividend yield looks covered by current payout levels.
The composite risk read is 5/10, putting it in moderate territory. With 30-day volatility of 33.3%, a beta of 0.59 and a maximum drawdown of 31.5%, position sizing matters here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
The horizons line up on buy — conviction 5 out of 10.

Top Market Events

Thermo Fisher Scientific NYSE:TMO has been selected by ImmuPharma as the key drug product and contract development...Thermo Fisher Scientific Inc. NYSE:TMO and Danaher Corporation NYSE:DHR are two of the world’s largest life sciences...Life sciences company Thermo Fisher NYSE:TMO announced in Q2 CY2026, with sales up 10.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 535.50
  • MACD momentum is negative

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 32.3 versus sector average of 30.6
  • Trading above the 200-day average of 535.50

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • P/E of 32.3 versus sector average of 30.6
  • Analyst targets imply +5.1% versus the current price
  • Profit margin of 15.0% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth10.50%
Profit Margin15.04%
P/E Ratio32.3
ROE13.51%
ROA5.13%
Debt/Equity80.58
P/B Ratio4.2
Op. Cash Flow$9.0B
Free Cash Flow$6.2B
Industry P/E30.6

Technical Analysis

TrendBullish
RSI52.3
Support$564.40
Resistance$647.00
MA 20$607.49
MA 50$563.26
MA 200$535.50
MACDBearish
VolumeStable
Fear & Greed Index92.25

Valuation

Fair Value$228.76
Target Price$631.42
Upside/Downside5.15%
GradeFair
TypeGrowth
Dividend Yield0.30%

Risk Assessment

Beta0.59
Volatility33.30%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.